Gene · 410
ARSA: arylsulfatase A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ARSA: arylsulfatase A. Genes, record 410. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/410
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P15289 | Arylsulfatase A | 507 | 10 | Ensembl, GeneID, HGNC |
Source UniProt
Patents83
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026067851 A | 2026-04-21 | 253 | P15289 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 37910 | P15289 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 37911 | P15289 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 40482 | P15289 | Espacenet |
| US 12410415 B2 | 2025-09-09 | 1 | P15289 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5524 | P15289 | Espacenet |
| WO 2025157942 A2 | 2025-07-31 | 1 | P15289 | Espacenet |
| JP 2025111747 A | 2025-07-30 | 152 | P15289 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5524 | P15289 | Espacenet |
| JP 2025522877 A | 2025-07-17 | 1041 | P15289 | Espacenet |
1 to 10 of 83
See all 83 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| ATIDARSAGENE AUTOTEMCEL | CHEMBL4802262 | ARSA exogenous gene | EXOGENOUS GENE |
Source ChEMBL
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants794
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ARSA papers | Newest fiscal year |
|---|---|---|---|
| R01DK067859 | Development of Assays for Newborn Screening and for Post-Screening Evaluation of Disease Severity | 14 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 6 | 2025 |
| U24HG007346 | Center for Critical Assessment of Genome Interpretation | 4 | 2025 |
| ZICMH002961 | Neurodevelopmental and Behavioral Phenotyping | 4 | 2025 |
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 3 | 2025 |
| R01NS017950 | Precursors of Stroke Incidence and Prognosis | 3 | 2025 |
| T32GM007526 | Medical Genetics Research Fellowship Program | 3 | 2025 |
| U54NS092090 | Developmental Synaptopathies Associated with TSC, PTEN, SHANK3 and SynGAP1 Pathogenic Variants | 3 | 2025 |
| I01BX004823 | Defining high- and low-risk APOE õ4 haplotypes for AlzheimerâÂÂs disease | 2 | 2025 |
| P01AG019724 | Frontotemporal Dementia: Genes, Images, and Emotions | 2 | 2025 |
1 to 10 of 794Source NIH's project files
See all 794 nih grantsPapers2,331
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mammalian Expression and Mass Spectrometric Characterization of Highly Active Human Arylsulfatase A. | Biotechnol J | 2026 | 42788422 | PubTator, text mining | PubMed |
| Leukodystrophy in Tanzania: A Case Study Highlighting Diagnostic Dilemmas and Clinical Implications. | Clin Case Rep | 2026 | 42787314 | PubTator, text mining | PubMed |
| Evidence Regarding Metachromatic Leukodystrophy Newborn Screening. | Pediatrics | 2026 | 42674587 | PubTator, text mining | PubMed |
| Preliminary Data of the First Year of Newborn Screening for Metachromatic Leukodystrophy (MLD) in Lombardy. | Int J Neonatal Screen | 2026 | 42496454 | PubTator, text mining | PubMed |
| Ultra-rare variants in LAMA2 are risk factors for frontotemporal dementia and motor neuron disease. | Hum Mol Genet | 2026 | 42165280 | PubTator, text mining | PubMed |
| Expression of sulfate pathway genes in human neurodevelopment. | J Neurogenet | 2026 | 42101182 | PubTator, text mining | PubMed |
| A single nucleotide polymorphism that affects oligodendroglial lineage cells may augment the consequences of neurotoxicants. | Neurotoxicology | 2026 | 42002102 | PubTator, text mining | PubMed |
| Identification of tofersen PD-response biomarkers in VALOR clinical trial CSF via multiplexed quantitative proteomics. | Cell Rep Med | 2026 | 41850233 | PubTator, text mining | PubMed |
| Genomic modifiers of malignant and neurodevelopmental phenotypes in individuals with PTEN hamartoma tumor syndrome. | NPJ Genom Med | 2026 | 41844650 | PubTator, text mining | PubMed |
| Exploring genetic drivers of unexplained venous thromboembolism through whole-exome sequencing. | Thromb Res | 2026 | 41831330 | PubTator, text mining | PubMed |
1 to 10 of 2,331
See all 2,331 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/410
GET https://conductscience.org/api/genes/v1/410/patents?page=2